Cerebrovascular Lesions in Down Syndrome Do Not Follow a Linear Course

by Hospital de la Santa Creu i Sant Pau

3 months ago
Down syndrome, Alzheimer, white matter hyperintensities (WMH)

A longitudinal study from the Institut de Recerca Sant Pau (IR Sant Pau), published in Alzheimer’s & Dementia, shows that these alterations can fluctuate and even decrease over time in the Down synd...

The therapeutic target against memory impairments in Down syndrome gains strength

by UPF - Universitat Pompeu Fabra

7 months ago
molecule AEF0217, Down syndrome, cannabinoid receptor 1, neurodegeneration

The experimental, long-term pharmacological treatment in a mice model for Down syndrome to reduce the activity of cannabinoid receptor 1 improves the memory defects associated with the syndrome even w...

Positive results of the clinical trial of a drug to improve cognitive function in Down syndrome

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

1 year ago
Down syndrome, molecule AEF0217, ICOD Project

Phase 1/2 of the clinical trial shows that the administration of the AEF0217 molecule developed by the biotech Aelis Farma, is safe and can improve key skills such as communication, social interaction...

Down syndrome linked to changes in mobile DNA fragments

by Centre for Genomic Regulation

2 years ago
Down syndrome, retrotransposons, lamivudina

A study conducted by IrsiCaixa —a centre jointly supported by the "la Caixa" Foundation and the Department of Health of the Generalitat de Catalunya— and the Centre for Genomic Regulation (CRG) de...

Aelis Farma announces good results from its first administration in humans for AEF0217, its first drug candidate for the treatment of cognitive disorders in Down syndrome

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

4 years ago
Down syndrome, Aelis Farma, AEF0217, ognitive disorders

This is a phase 1 clinical trial part of the European H2020 ICOD project (Improving COgnition in Down syndrome) coordinated by Prof. Raphael de la Torre Fornell.

New plasma biomarker to detect Alzheimer’s disease in Down syndrome individuals

by Hospital de la Santa Creu i Sant Pau

5 years ago
plasma biomarker, Alzheimer’s Disease, Down syndrome

International collaboration led by researchers at the Sant Pau Reseach Institute – IIB Sant Pau in Barcelona, Spain, shows effectiveness of a plasma biomarker to detect Alzheimer’s Disease in D...

International study finds increased mortality in adults with Down syndrome

by Centre for Genomic Regulation

5 years ago
genetic disorder, COVID-19, Down syndrome, Adults, vaccinations, mortality

Research led by King’s College London in collaboration with the Centre for Genomic Regulation (CRG) and the Trisomy 21 Research Society (T21RS) finds increased COVID-19 mortality among adults wit...

Connecta Therapeutics raises €1.7 M in a round led by Inveready to develop new treatment for fragile X syndrome

by Inveready

6 years ago
Inveready, Prous Institute for Biomedical Research, CDTI, Connecta Therapeutics, FXS, neuroplasticity, autism, Rett syndrome, Down syndrome

Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...

Down syndrome in Europe – has the disease epidemiology changed over the last quarter-century?

by European Commission - Joint Research Centre

7 years ago
Database, Down syndrome, epidemiology, Europe

Of the 5.2 million births in the European Union (EU) each year, approximately 104,000 (2.5%) will be born with congenital anomalies.

Major international project aims to identify causes of dementia

by Centre for Genomic Regulation

8 years ago
dementia, Alzheimer, Parkinson, Down Syndrome

European scientists have launched a research programme, which aims to identify common causes of dementia in Alzheimer’s Disease, Parkinson’s Disease and Down Syndrome. The project brings together...